Recursion's REC-4881 Milestone And Cash Runway Shift Risk Reward Profile [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations with Sanofi and Roche/Genentech. Management indicates its cash runway now extends into early 2028 through what it describes as disciplined execution. Recursion Pharmaceuticals positions itself as an AI driven drug discovery company focused on bringing therapies to patients, including those with rare diseases. For retail investors watching the intersection of technology and biotech, REC-4881 reaching clinical proof of concept in familial adenomatous polyposis is an early sign that the company's platform is starting to be tested in real patient settings. The recent collaboration milestones with Sanofi and Roche/Genentech, together with an extended cash runway, give Recursion
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion: Nvidia Sells Out, Collaboration Still Alive, Data Ahead [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals (RXRX) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RXRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fromMarketBeat
- Recursion Pharmaceuticals (RXRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Recursion Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) had its "neutral" rating reaffirmed by Bank of America Corporation.MarketBeat
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 3/3/26 - Form 144
- 2/25/26 - Form S-8
- 2/25/26 - Form 424B5
- RXRX's page on the SEC website